Bloomberg Law
Drug, Device Manufacturers to Face Hill Scrutiny in 2019
January 8, 2019
Combating high drug and device prices is a bipartisan goal in Congress, and House Democrats in control of key oversight committees have made clear their plans to pursue investigations putting pharma CEOs under scrutiny. Manufacturers need to prep now to explain policies and prepare for public relations issues.
得意分野
Suggested News & Insights
Sidley Healthcare Investment Conference 2026Tuesday, September 22, 2026DOJ Releases FOCUS Questionnaire to Assist in Evaluating Qui Tams Filed by Data MinersJuly 20, 2026Sidley Shortlisted in 16 Categories at the LMG Life Sciences Americas Awards 2026July 20, 2026June DOJ/SBA FCA Settlement Highlights Continued Focus on Contractor ComplianceJuly 15, 2026OIG Signals Further Support for Manufacturer-Sponsored Testing Programs with Fourth Favorable Advisory OpinionJuly 8, 2026Texas Supreme Court Imposes Materiality Requirement on Texas Healthcare Fraud Omissions ClaimsJuly 7, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory